Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, established in 2000. It is dedicated to reducing global inequities by focusing on improving health, alleviating extreme poverty, and supporting educational initiatives. The foundation also engages in community giving within the Pacific Northwest, promoting strategies and programs that assist low-income families. With regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom, the foundation is governed by its co-founders, Bill and Melinda Gates, along with trustee Warren Buffett. Its mission encompasses a wide range of global challenges, aiming to create lasting change through targeted grant-making and programmatic efforts.

Harish Iyer

Deputy Director, Digital and Health Innovation

Chris Karp

Director, Global Health Discovery and Translational Sciences

Keith Klugman

Director

Trevor Mundel

President, Global Health

Rob Nabors

Director, North America

Lynda Stuart

Deputy Director

Mark Suzman

President, Global Policy and Advocacy

Chris Wilson

Director

Past deals in Grant

Leinco Technologies

Grant in 2025
Leinco Technologies is a company that specializes in the development of high-purity monoclonal antibodies, proteins, and various reagents specifically for the diagnostic and biopharmaceutical industries. They provide a range of services, including in vitro antibody and protein production, antibody conjugations, and cell banking. Leinco Technologies focuses on augmenting the early discovery process in life science research and diagnostics, as well as contributing to the innovative development of protein therapeutics. Their expertise in optimizing and adapting products enables clients to effectively meet their research and development needs.

ReciBioPharm

Grant in 2025
ReciBioPharm operates as a biologics company. ReciBioPharm is a division of Recipharm.

Aptitude Medical Systems

Grant in 2025
Aptitude Medical Systems provides the next generation of diagnostic testing, delivering lab-quality results quickly and easily wherever people need them. The company's mission is to combine the sensitivity and specificity of lab-based PCR tests with the cost-effectiveness and scalability of antigen tests. The company has developed proprietary synthetic molecules, known as aptamers, which enhance molecular recognition capabilities beyond traditional antibody technologies. This innovation enables early detection and treatment of diseases such as cancer, autoimmune disorders, and heart disease.

Biosurfaces

Grant in 2024
BioSurfaces is a provider of medical care services intended to be offered by augmenting existing and emerging medical approaches with nanotechnology. The company's services applies room-temperature electrospinning process to allow drug loading into each fiber, providing a reservoir for sustained drug release at the implant site, enabling customers to make devices and coatings as thin as 10um which can treat diseases at site.

Dyadic International

Grant in 2024
Dyadic International, Inc., is a global biotechnology company headquartered in Jupiter, Florida with its research and development center in the Netherlands. Dyadic uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce

Insud Pharma

Grant in 2024
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health.

Canyon GBS

Grant in 2024
Based in the vibrant Phoenix Metro Area and supported by a global team, Canyon GBS® is a pioneering tech company crafting impactful solutions powered by AI. With a diverse range of offerings tailored for sectors such as higher education, public sector government agencies, non-profits, and small businesses, Canyon GBS® is dedicated to enhancing operational efficiency. Our mission is to equip organizations with powerful yet accessible AI-powered technology to better serve their constituents. Through our relentless pursuit of innovation and customer-centric approach, Canyon GBS® strives to be a trusted partner in navigating today's digital landscape.

PopVax

Grant in 2024
PopVax is a biotechnology company that developing novel mRNA vaccines and therapeutics using computational protein design.

ApiJect

Grant in 2024
ApiJect Systems is a medical technology company focused on revolutionizing the delivery of injectable medications through its innovative platform for prefilled, single-dose injectors. By utilizing medical-grade plastic resin, ApiJect replaces traditional materials like glass and rubber, streamlining the manufacturing process and significantly reducing environmental impact. The ApiJect Platform enables pharmaceutical and biotech companies to efficiently produce scalable prefilled injectors, either on proprietary Blow-Fill-Seal packaging lines or through partnerships with other manufacturers. This approach not only simplifies the supply chain but also accelerates production times, transforming a multi-step process that typically takes weeks into a rapid, efficient operation. Through these advancements, ApiJect aims to make prefilled injections more affordable and accessible to patients globally.

CanSino Biologics

Grant in 2024
CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Imperial College London

Grant in 2024
Imperial College London is a prestigious institution renowned for its emphasis on science, technology, engineering, medicine, and business (STEMB). The university is dedicated to leveraging scientific research to tackle global challenges and operates across its London campuses and an extensive international network. It fosters an environment that encourages entrepreneurship and the exchange of innovative ideas, thereby enhancing its research-intensive educational offerings. The Imperial College Business School, a part of the institution, aims to cultivate future business leaders by integrating business acumen with technological advancements. Through its cutting-edge research, the school informs advanced degree programs and collaborates with governments, policymakers, and industry leaders on various projects. This collaboration promotes innovative and practical solutions to real-world problems, benefiting both business and society. The college also supports lifelong professional development and boasts a global alumni network, helping graduates achieve successful careers across diverse industries worldwide.

Upsolve

Grant in 2024
Upsolve helps low-income Americans get a fresh start after sudden financial shocks by automating bankruptcy. It provides a free online tool that asks users questions and generates a Chapter 7 bankruptcy forms, after that, the company's lawyers will review the forms.Jonathan Petts and Rohan Pavuluri founded Upsolve in June 2016, with its headquarters in New York City.

Legume Technology

Grant in 2024
Legume Technology is a producer of organic, contaminant-free, biostimulant products that are proven to increase yield. They provide services such as physicochemical improvement of pellets, compatibility testing, coating machinery, private labelling, marketing support, registration support from legume technology, pre-treatment inoculant training, application strategy and techniques. Their products like liquifix, liquifix 120, legumefix, molyfix, rootfix, extensive,and mycofix. They provide support for crops such as soya, peas, lupin, lucerne, wheat, chickpeas, clover, corn, and sunflower.

Immorna

Grant in 2024
Immorna is a biotechnology company focused on developing RNA-based therapeutics and vaccines. The company employs various RNA platforms, including conventional, self-replicating, and circular RNA, to create innovative treatments. Immorna has established a comprehensive central management console for RNA synthesis, purification, and analytical testing, which facilitates both clinical and commercial development. Additionally, the company has developed advanced screening tools and a range of RNA delivery vehicles, such as polymers and lipid nanoparticles, incorporating proprietary ionizable cationic lipids. This robust infrastructure positions Immorna to contribute significantly to the field of RNA therapeutics.

RiseKit

Grant in 2024
RiseKit, Inc. is a Chicago-based company that provides software aimed at connecting entry to mid-level job candidates, particularly from underserved communities, with employment opportunities, training programs, and supportive services. Founded in 2016, RiseKit addresses employment barriers by ensuring that job seekers have access to career paths regardless of their geographic or socio-economic circumstances. The company serves a diverse clientele, including nonprofits, government agencies, and employers, helping them efficiently support job candidates and measure outcomes. By facilitating connections between untapped talent and organizations looking to hire, RiseKit not only empowers individuals to overcome obstacles to employment but also assists community partners in enhancing their capabilities through scalable software solutions.

Snipr Biome

Grant in 2024
Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Alan Turing Institute

Grant in 2024
The Alan Turing Institute is the national institute for data science. The Institute is named in honour of Alan Turing (23 June 1912 – 7 June 1954), whose pioneering work in theoretical and applied mathematics, engineering and computing are considered to be the key disciplines comprising the emerging field of data science.

Ben-Gurion University of the Negev

Grant in 2024
Ben-Gurion University of the Negev is one of Israel’s leading research universities and among the world leaders in many fields. It has around 20,000 students and 4,000 faculty members in the Faculties of Engineering Sciences; Health Sciences; Natural Sciences; the Pinchas Sapir Faculty of Humanities and Social Sciences; the Guilford Glazer Faculty of Business and Management; the Joyce and Irving Goldman School of Medicine; the Kreitman School of Advanced Graduate Studies; and the Albert Katz International School for Desert Studies. More than 100,000 alumni play important roles in all areas of research and development, industry, health care, the economy, society, culture and education in Israel. The University has three main campuses: The Marcus Family Campus in Beer-Sheva; the research campus at Sede Boqer and the Eilat Campus, and is home to national and multi-disciplinary research institutes: the National Institute for Biotechnology in the Negev; the National Institute of Solar Energy; the Ilse Katz Institute for Nanoscale Science and Technology; the Jacob Blaustein Institutes for Desert Research; the Ben-Gurion Research Institute for the Study of Israel & Zionism, and Heksherim - The Research Institute for Jewish and Israeli Literature and Culture.

Shomvob

Grant in 2024
Shomvob is an integrated fintech and HR-tech platform designed to serve the emerging frontline workforce in Bangladesh. The platform focuses on creating job opportunities by assisting individuals in developing a digital professional identity and expanding their professional networks. By aligning job offerings with users' skills, qualifications, and expectations, Shomvob enhances employment prospects. Additionally, the company promotes financial inclusion through a comprehensive payroll financing product, further supporting the workforce in accessing essential financial services.

Surf Bio

Grant in 2024
Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.

Owlstone Medical

Grant in 2024
Owlstone Medical Ltd is a diagnostics company based in Cambridge, United Kingdom, specializing in non-invasive breath-based diagnostic tools aimed at the early detection of diseases, including cancer and respiratory conditions. The company develops a range of innovative products, including its Breath Biopsy platform, which utilizes advanced technology to identify volatile organic compounds in breath samples. Its offerings include FAIMS technology for medical applications, Lonestar for disease biomarker detection, and ReCIVA breath samplers for in vitro analysis. Owlstone Medical's technology has significant applications in various medical fields, such as lung cancer, bowel cancer, and gastrointestinal disorders. The company is also exploring the development of a portable hand-held device that promises high sensitivity and selectivity for chemical detection, with potential applications across multiple markets, including military and industrial sectors. Owlstone Medical aims to become a leader in non-invasive diagnostics, with ongoing collaborations and trials, including contracts with the UK National Health Service for lung cancer screening initiatives.

Sibel Health

Grant in 2024
Sibel Health focuses on developing advanced monitoring solutions that enhance healthcare delivery and improve patient outcomes through wireless vital signs monitoring and data integration. The company creates soft, flexible sensors capable of measuring critical parameters such as heart rate, respiratory rate, skin temperature, body position, and patient activities, including those of pregnant mothers. Sibel Health's clinical-grade digital monitoring products are portable and user-friendly, ensuring accuracy and reliability. Additionally, the company offers motion sensor-based chest and limb monitoring devices, along with a comprehensive physiological monitoring platform that incorporates advanced analytics. These innovations are designed to support medical professionals in both clinical care and research applications, particularly within the pharmaceutical and clinical research sectors.

Corner Therapeutics

Grant in 2024
Corner Therapeutics is a biotechnology research company focused on immunotherapy. It specializes in developing technologies that stimulate exceptional memory T cells to achieve lifelong immunity. The company utilizes a versatile dendritic cell hyperactivation platform that induces strong T-cell responses, aiming to provide robust and durable immunity against a wide range of cancers and infectious diseases. By enhancing T-cell activation, Corner Therapeutics seeks to enable healthcare providers to promote lasting immunity and optimize immune regulation.

Ginkgo Bioworks

Grant in 2024
Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

Antibody Solutions

Grant in 2024
Antibody Solutions provides antigen design, polyclonal antibody generation, research and drug development for biopharmaceutical companies.

Detect-Ion

Grant in 2024
Detect-ION is a cutting-edge deep-tech startup that specializes in the development of sensors and systems for a variety of applications, with a focus on innovation and technological excellence.

Phase Genomics

Grant in 2024
Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Food Fortification Initiative

Grant in 2024
Food Fortification Initiative is a non-profit organization that provides the fortification of industrially milled flour and rice globally.

PhaSER Biomedical

Grant in 2024
PhaSER Biomedical is Exploiting the 8HUM mouse, a unique mouse model with multiple utilities in drug discovery, and development.

C16 Biosciences

Grant in 2024
C16 Biosciences, Inc. is a biotechnology company based in New York, established in 2017, specializing in the production of sustainable alternatives to palm oil through microbiology and fermentation processes. The firm focuses on creating innovative ingredients for food manufacturers, refiners, and consumers, aiming to decarbonize the supply chains of consumer product brands. C16 Biosciences has developed the Palmless™ platform, which features its first biodesigned ingredient, Torula oil—a premium bioactive oil known for its clinically proven benefits for skin and hair health. By leveraging biomanufacturing techniques, the company provides scalable and sustainable options, addressing the demand for environmentally friendly alternatives in the oil and fat market.

ProteinLogic

Grant in 2024
ProteinLogic’s ImmiPrint® technology impacts the emerging market for diagnostic, predictive, prognostic and other biomarker applications.

Sail Biomedicines

Grant in 2024
Sail Biomedicines is a flagship pioneering company that is developing tomorrow's medicines today using life's language. Sail's platform combines first-in-class translatable circular RNA technology (Endless RNATM or eRNA) with unique programmable nanoparticles based on natural components to thoroughly program medications for the first time.

Radiant Biotherapeutics

Grant in 2023
Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

LTS Lohmann Therapie-Systeme AG

Grant in 2023
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Brightseed

Grant in 2023
Brightseed, Inc. is a biotechnology company based in San Francisco, California, that specializes in the discovery of bioactive compounds in plants to enhance human health. Utilizing its advanced Forager platform, which employs artificial intelligence and machine learning algorithms, Brightseed accelerates the identification and validation of clinically beneficial molecules. This innovative approach enables the company to uncover connections between natural compounds and health outcomes, revealing the potential of bioactives that have previously remained uncharted. By integrating these discoveries back into the food supply chain, Brightseed collaborates with various companies across the consumer health continuum to develop science-backed health solutions aimed at managing chronic diseases and improving overall quality of life. Founded in 2017, Brightseed is committed to exploring the untapped resources of the plant kingdom to address pressing health challenges.

Evotec

Grant in 2023
Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Ginkgo Bioworks

Grant in 2023
Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

Vitrivax

Grant in 2023
VitriVax is a biotechnology startup based in Boulder, Colorado, focused on developing an innovative vaccine formulation platform. The company utilizes its proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology to create vaccines that are more effective, affordable, and accessible worldwide. This technology addresses the challenges associated with vaccine stability and administration by enabling the development of thermostable, single-shot vaccines that can effectively incorporate both prime and booster doses. VitriVax's advancements in vaccine formulation aim to eliminate barriers to global vaccination, ultimately enhancing immune responses for a broad range of medical indications. The company has received significant funding, including over $5 million from various sources such as the National Institutes of Health, the National Science Foundation, and the Bill and Melinda Gates Foundation, to support its mission.

LTS Lohmann Therapie-Systeme AG

Grant in 2023
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Micron Biomedical

Grant in 2023
Micron Biomedical is a clinical-stage biopharmaceutical company established in 2014 and located in Atlanta, Georgia. The company focuses on developing microneedle patches specifically for vaccines, including those for influenza and polio. Its innovative microneedle technology aims to improve protective and therapeutic effects while enhancing patient compliance and simplifying the administration process. By leveraging this technology, Micron Biomedical seeks to facilitate the development of effective vaccines, addressing important public health needs.

Osmo

Grant in 2023
Osmo gives computers a sense of smell that improves the health and well-being of human life. Osmo brings together frontier AI and olfactory science to tackle a historic challenge. While they are initially focused on the intricate world of fragrance, their ultimate objective is to enhance the health and well-being of human life through the sense of smell.

Philips

Grant in 2023
Philips is a global technology company that specializes in healthcare, consumer lifestyle, and lighting products, solutions, and services. The company provides a wide range of offerings, including healthcare solutions, professional lighting products, oral healthcare items, and innovative display technologies. For consumers, Philips offers electronic products in categories such as sound and vision, personal care, mother and child care, housewares, and lighting. The company's commitment to improving health and well-being is evident in its focus on meaningful innovation and its efforts to address healthcare inequalities through initiatives like the Philips Foundation, which aims to enhance access to quality healthcare for disadvantaged communities.

Axmed

Grant in 2023
Axmed is a business focuses on LMICs and strengthens the purchasing power of these markets to ensure the supply of cost-effective, high-quality medicines. We partner exclusively with authorized, high-quality pharmaceutical companies and certified caregivers to accelerate access to medicines.

CanSinoBIO

Grant in 2023
Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

Salient

Grant in 2023
Salient creates a weather intelligence platform that combines novel ocean and land-surface data with machine learning and climate expertise to provide accurate subseasonal-to-seasonal (S2S) weather forecasts 2 to 52 weeks ahead. Salient's tools sift through large datasets to identify complex climate system relationships in order to provide accurate forecasts used in agriculture, energy, finance, supply chain, and other industries. Salient utilizes scientific knowledge to assist individuals and organizations in better understanding and preparing for the increasing volatility of climate change.

STRM.BIO

Grant in 2023
STRM.BIO is a biotechnology company focused on enhancing gene therapy delivery through the use of extracellular vesicles (EVs). These natural carriers, which transport nucleic acids and proteins, offer innate targeting capabilities and can be mass-produced efficiently. By leveraging EVs, STRM.BIO aims to create a new class of therapeutics that not only introduces novel treatments but also improves the effectiveness of existing therapies. The company's approach seeks to simplify and enhance the safety of gene therapy delivery directly to patients, fulfilling the potential of this innovative medical field.

AN2 Therapeutics

Grant in 2023
AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

GE HealthCare Technologies

Grant in 2023
GE Healthcare is a multinational healthcare company based in Chicago, Illinois, that specializes in manufacturing a diverse range of medical equipment and technologies. Founded in 1892, the company offers products and services including medical imaging, information technologies, medical diagnostics, and patient monitoring systems. GE Healthcare also supports drug discovery and biopharmaceutical manufacturing through intelligent devices and data analytics. The company aims to enhance patient care and outcomes by providing innovative healthcare solutions utilized in hospitals, clinics, research institutions, and pharmaceutical companies globally. By focusing on precision health and digitizing healthcare, GE Healthcare seeks to improve productivity and health outcomes for patients and healthcare providers alike. Additionally, the company pursues an aggressive acquisition strategy to strengthen its presence in emerging markets and expand its life sciences portfolio.

Fulbright University Vietnam

Grant in 2023
Vietnam faces a disconnect between its educational priorities and the demand for skilled employees. While Vietnamese students perform well on standard academic tests, employers consistently report that students lack the skills needed to excel, as reflected in the high underemployment rate of college graduates.

Nuoc.Solutions

Grant in 2023
Nuoc.Solutions aims to create and foster innovative, sustainable, and efficient solutions to pressing water problems in Vietnam.

EHA Clinics

Grant in 2023
EHA Clinics is dedicated to providing accessible, effective, and affordable healthcare services. The organization offers a comprehensive healthcare network that includes routine medical care, laboratory services, pharmacy, optometry, dental care, urgent care, and specialist consultations. EHA Clinics ensures that members have round-the-clock access to healthcare through various channels, including physical locations, telehealth virtual visits, and home care services. By leveraging technology and a skilled team, EHA Clinics aims to enhance the healthcare experience, improve patient outcomes, and offer competitive pricing for individual, family, and business members.

Lahore University of Management Sciences

Grant in 2023
The Lahore University of Management Sciences (LUMS) is a national university, established by sponsors belonging to the country’s leading private and public sector corporations. The goal of the sponsors is to develop an institution, which would provide rigorous academic and intellectual training and a viable alternative to education comparable to leading universities across the world.

Aptitude Medical Systems

Grant in 2023
Aptitude Medical Systems provides the next generation of diagnostic testing, delivering lab-quality results quickly and easily wherever people need them. The company's mission is to combine the sensitivity and specificity of lab-based PCR tests with the cost-effectiveness and scalability of antigen tests. The company has developed proprietary synthetic molecules, known as aptamers, which enhance molecular recognition capabilities beyond traditional antibody technologies. This innovation enables early detection and treatment of diseases such as cancer, autoimmune disorders, and heart disease.

CO-DIAGNOSTICS

Grant in 2023
Co-Diagnostics is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

SoapBox Labs

Grant in 2023
Soapbox Labs specializes in child-specific speech recognition technology that accurately captures the unique speech patterns and idiosyncrasies of children. The company's innovative voice engine is designed to support a variety of applications, including toys, gaming, robotics, augmented and virtual reality, and educational tools focused on literacy and language learning. By providing immediate and precise feedback, Soapbox Labs enhances the learning experience for children across different accents, dialects, and developmental stages. Their technology is fully compliant with COPPA and GDPR regulations, ensuring a safe environment for young users. With solutions available both online and offline, Soapbox Labs aims to foster effective voice-enabled interactions for children.

Myna Mahila Foundation

Grant in 2023
Myna Mahila Foundation is a non-governmental organization that provides employment and skills to women in slum neighborhoods.

Latham Biopharm

Grant in 2023
Latham BioPharm Group (LBG) provides the insight, knowledge, and network to unite teams and technologies in the Life Sciences. They provide the depth of expertise necessary to advance your programs, by providing a range of life science services including business development, program management, CMC, quality, regulatory, and strategic consulting with proven experience in biodefense/pandemic response and strategic product development. Our team has an average of over 20 years’ experience and many have served as senior executives at companies ranging from start-ups to Fortune 200 companies. A number of us have also held senior level positions within the US government. For over twenty years, they have helped clients identify, evaluate, fund, manage, and monetize opportunities in a wide variety of business segments, generating over $1 billion in government funding and over $100 million in licensing fees and investments. On the front end, they assist clients in evaluating critical business decisions and connecting with the target markets to assess opportunities with our Strategy and Portfolio Analysis, Market Research, and Commercial and Government Asset Analysis offerings. They then assist in finding and securing funding through our Business Development and Non-Dilutive Funding Services. Once funded, they drive successful advancement to a targeted value-inflection point through our Program Management and Product Development Team services.

Aegis Life

Grant in 2023
Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. This technology, developed over two decades, is designed to facilitate the rapid development and commercialization of vaccines and therapeutics aimed at preventing and treating infectious diseases. Aegis Life's innovative approach supports the pharmaceutical industry in accelerating the discovery, clinical development, and manufacturing processes for vaccines and treatments, particularly in response to emerging health threats such as COVID-19.

Council for Scientific and Industrial Research

Grant in 2023
The Council for Scientific and Industrial Research, commonly known as the CSIR, is a world-class African research and development organisation established through an Act of Parliament in 1945. The CSIR undertakes directed, multidisciplinary research and technological innovation that contributes to the improved quality of life of South Africans. The organisation plays a key role in supporting government’s programmes through directed research that is aligned with the country’s priorities, the organisation’s mandate and its science, engineering and technology competences. Key issues that the CSIR seeks to address through various interventions include: creating a vibrant economy and employment opportunities; building a capable state that is able to consistently deliver high-quality services for all South Africans; contributing to the development of economic and social infrastructure like transport, energy, water resources and ICT networks. The CSIR’s shareholder is the South African Parliament, held in proxy by the Minister of Science and Technology.

Hyperfine

Grant in 2023
Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

Medicines for All Institute

Grant in 2023
The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Vir Biotechnology

Grant in 2023
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Audere

Grant in 2023
Audere is a digital health nonprofit developing software to improve global health in underserved communities.

Smart Immune

Grant in 2023
Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Osivax

Grant in 2023
Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

Evotec

Grant in 2023
Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

SpyBiotech

Grant in 2023
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

DelSiTech

Grant in 2023
DelSiTech, Ltd. is a technology specialist based in Turku, Finland, focused on developing and licensing long-term controlled drug delivery systems. Established in 2001, the company specializes in biodegradable silica-based implants and injectable formulations for the controlled release of small molecular drugs, biopharmaceuticals, and viral vectors. DelSiTech's innovative technology embeds active ingredients within a silica matrix, facilitating parenteral and local administration through injectable depot, implant, and eye drop dosage forms. By providing expertise in controlled release products, DelSiTech aims to address various drug-related challenges and support clients in the development of supergeneric solutions.

Zoetis

Grant in 2023
Zoetis Inc. is a leading company in the animal health sector, focused on the discovery, development, manufacturing, and commercialization of medicines, vaccines, and diagnostic products for both livestock and companion animals. The company's diverse product portfolio includes vaccines for various diseases, anti-infectives to combat infections, and parasiticides to eliminate parasites. Additionally, Zoetis offers pharmaceutical products for pain management, reproductive health, and dermatological conditions, as well as medicated feed additives for livestock. The company also provides diagnostic tools, including portable blood and urine analysis systems, rapid immunoassay tests, and other non-pharmaceutical products. With a significant revenue contribution from companion animals, particularly in the United States, Zoetis markets its offerings to veterinarians, livestock producers, and retail outlets globally. Founded in 1952 and headquartered in Parsippany, New Jersey, Zoetis has established itself as a key player in advancing animal health and well-being through a commitment to research and innovation.

Beeck Center for Social Impact + Innovation

Grant in 2023
The Beeck Center at Georgetown University was launched in 2014 through the generosity of Alberto and Olga Maria Beeck. Part lab, part think tank and part classroom, the Center engages global leaders to drive social change at scale.

MIP Discovery

Grant in 2023
MIP Discovery is a technology leader specializing in the development of molecularly imprinted polymers (MIPs) and nanoMIPs, which are plastic antibodies designed to address the limitations of traditional MIP manufacturing methods. The company's innovations feature polymers and antibodies that incorporate a single binding site for specific targets, allowing them to be effectively fused to solid substrates, such as sensor surfaces. This capability provides hospitals with highly effective reagents suitable for a variety of applications, including point-of-care diagnostics and field-based testing, thereby enhancing the efficiency and accuracy of medical testing.

UW Medicine

Grant in 2023
UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

VisualDx

Grant in 2023
VisualDx is a clinical decision support system that aims to improve diagnostic accuracy and patient safety in healthcare settings. By integrating a curated medical image library with a robust search engine, it provides clinicians with patient-specific answers swiftly, facilitating informed therapeutic decisions. The platform encompasses high-quality images covering a range of both pediatric and adult medical conditions. Used by over 2,300 hospitals, clinics, and medical schools globally, VisualDx enhances point-of-care decisions and fosters better patient engagement, enabling healthcare providers to deliver timely and effective care.

LumiraDx

Grant in 2022
LumiraDx Ltd, incorporated in 2016 and based in London, is a next-generation healthcare company specializing in point-of-care diagnostics. The company manufactures a diagnostic platform designed to provide lab-comparable performance across a wide range of tests, enhancing patient-centered care. LumiraDx aims to simplify and improve diagnostic-led care by offering a compact, portable instrument paired with advanced, low-cost test strips and seamless digital connectivity. Its solutions are focused on achieving healthcare transformation goals by delivering integrated and informed care, resulting in safer, more efficient practices with better patient outcomes. The company operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated in the U.S.

Aspen Pharmacare Holdings

Grant in 2022
Aspen Pharmacare Holdings Limited is a global pharmaceutical company headquartered in Durban, South Africa, specializing in the manufacture and supply of both branded and generic pharmaceutical products. It operates primarily through two segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a diverse range of products, including general anaesthetics, muscle relaxants, cytotoxic medications, and injectable anticoagulants, particularly focusing on low molecular weight heparins and Xa inhibitors. The company also engages in the contract production and supply of active pharmaceutical ingredients (APIs) and finished pharmaceuticals for third parties. With a presence in over 150 countries, Aspen serves various markets, including South Africa, Australia, and several nations across Europe and Asia. Its extensive capabilities in manufacturing encompass both API and finished dosage forms, addressing a wide array of therapeutic needs. Founded in 1850, Aspen has expanded its reach significantly through strategic acquisitions, enhancing its footprint in emerging markets and contributing to a diverse portfolio of healthcare solutions.

ExploRNA Therapeutics

Grant in 2022
ExploRNA Therapeutics creates revolutionary advancements in the use of mRNA as a therapeutic platform, implements those ideas into distinct therapeutic programs, and provides technology, a therapeutic platform, and medicines to pharmaceutical partners.

Touchlight Genetics

Grant in 2022
Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, it has developed the proTL synthetic DNA platform, which allows for the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach supports various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. The company boasts a skilled scientific and drug development team, led by founder and CEO Jonny Ohlson, and includes experienced professionals such as Clive Dix and John Tite. Touchlight has established partnerships with several leading academic institutions, including Imperial College London and the University of Pennsylvania, to advance its research and development efforts. The company has successfully patented its synthetic DNA platform and demonstrated therapeutic proof-of-principle through collaboration with these academic partners.

Dare Bioscience

Grant in 2022
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Cyclica

Grant in 2022
Cyclica Inc. is a Toronto-based company that specializes in enhancing the drug discovery process through its integrated cloud-based platform, which leverages artificial intelligence and biophysics. The company offers two main technologies: Ligand Design, which generates novel molecules and filters them based on various properties, and Ligand Express, a platform that screens small-molecule drugs against structurally-characterized protein repositories to assess poly-pharmacological profiles. This innovative approach allows pharmaceutical scientists to identify potential ligand-protein interactions, prioritize lead candidates, and explore opportunities for drug repurposing while also understanding potential adverse effects. Cyclica has established a strategic partnership with AUM Biosciences and has been operational since its incorporation in 2010.

Contro

Grant in 2022
Contro is an online prescription and delivery service for sexual health and confidence products such as birth control and erectile dysfunction treatment. Contro, through its secure digital platform, allows individuals to take control of their personal wellness by offering a convenient, affordable and discreet subscription service. Offering a cancel anytime policy, Contro makes it easier than ever to obtain sexual health products in South Africa.

Bayer

Grant in 2022
Bayer is a global enterprise based in Germany, specializing in life sciences with a strong focus on health care and agriculture. The company develops and commercializes a wide range of products, including pharmaceuticals, consumer health items, and crop science solutions. Bayer's pharmaceutical division offers a variety of medications, while its consumer health segment includes vitamins and food supplements. In agriculture, Bayer provides seeds and crop protection products, including pesticides, herbicides, and fungicides, significantly expanded through the acquisition of Monsanto. Additionally, Bayer is a leader in animal health, contributing to the well-being of both human and animal populations. Overall, Bayer aims to create innovative solutions that address critical challenges in health and nutrition.

NUVISAN GmbH

Grant in 2022
Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.